Update on Immune Checkpoint Inhibitors in Lung Cancer
Open Access
- 1 January 2014
- journal article
- case report
- Published by SAGE Publications in Cancer Control
- Vol. 21 (1), 80-89
- https://doi.org/10.1177/107327481402100112
Abstract
The immune checkpoint proteins, including the B7/CD28 receptor superfamily, have become increasingly important targets for pharmacologic blockade. Several classes of new agents have impressive clinical activity, and their eventual approval for treatment of lung cancer seems likely. This article discusses the current development of these agents, including the CTLA-4, PD-1, and PD-L1 inhibitory pathways, killer immunoglobulin receptor (KIR) inhibition, and other checkpoint proteins. Ipilimumab in combination with chemotherapy has exhibited encouraging results in small-cell and non–small-cell lung cancer alike. Reported phase I trials of the monoclonal antibodies nivolumab, MK-3475, MEDI4736, and MPDL3280A are demonstrating durable overall radiological response rates in the 20% to 25% range in lung cancer. This exceptional activity includes squamous lung cancers, a population historically bereft of significant therapeutic advances. Retrospective examination of tumor PD-L1 expression suggests that PD-L1 may eventually be evaluable as a predictive biomarker. Dual checkpoint blockade strategies, such as those combining anti-CTLA-4, anti-LAG-3, or anti-KIR, are being tested to increase the proportion and durability of tumor responses. Examination of acquired immune resistance and post-immunotherapy relapse strategies are underway. These emerging antibodies hold great potential for the systemic control of epithelial cancers such as lung cancer.Keywords
This publication has 87 references indexed in Scilit:
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trialThe Lancet Oncology, 2013
- What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?Annals of Oncology, 2012
- Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)Lung Cancer, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Impact of Collection and Storage of Lung Tumor Tissue on Whole Genome Expression ProfilingThe Journal of Molecular Diagnostics, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Delivering affordable cancer care in high-income countriesThe Lancet Oncology, 2011
- PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in miceThe Journal of Experimental Medicine, 2011
- Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2010
- No evidence for dualism in function and receptors: PD‐L2/B7‐DC is an inhibitory regulator of human T cell activationEuropean Journal of Immunology, 2006